Hinge Health (NYSE:HNGE) Given New $131.00 Price Target at Morgan Stanley

Hinge Health (NYSE:HNGE) had its price target increased by equities research analysts at Morgan Stanley from $117.00 to $131.00 in a report released on Tuesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Morgan Stanley‘s price target points to a potential upside of 12.79% from the company’s current price.

HNGE has been the subject of a number of other reports. Evercore reissued an “outperform” rating and issued a $105.00 price objective on shares of Hinge Health in a research note on Wednesday, August 5th. Stifel Nicolaus lifted their target price on shares of Hinge Health from $130.00 to $135.00 and gave the company a “buy” rating in a research note on Tuesday. Canaccord Genuity Group upped their target price on shares of Hinge Health from $105.00 to $134.00 and gave the stock a “buy” rating in a report on Tuesday. Citigroup reiterated an “outperform” rating on shares of Hinge Health in a research note on Monday, July 27th. Finally, Barclays raised their price target on Hinge Health from $100.00 to $110.00 and gave the company an “overweight” rating in a report on Monday, October 12th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat, Hinge Health presently has an average rating of “Moderate Buy” and a consensus price target of $118.93.

Hinge Health Stock Up 0.6%

HNGE traded up $0.66 during midday trading on Tuesday, reaching $116.14. The company had a trading volume of 1,479,849 shares, compared to its average volume of 1,624,486. The business has a 50-day moving average of $98.66 and a two-hundred day moving average of $67.35. Hinge Health has a 1 year low of $30.08 and a 1 year high of $118.86. The company has a market cap of $9.37 billion, a P/E ratio of 90.73 and a beta of 1.37.

Hinge Health (NYSE:HNGE) last posted its quarterly earnings data on Monday, November 2nd. The company reported $0.71 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.44. The firm had revenue of $234.97 million for the quarter. Hinge Health had a return on equity of 51.60% and a net margin of 15.15%. The firm’s quarterly revenue was up 52.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.02) earnings per share. On average, equities research analysts predict that Hinge Health will post 1.25 EPS for the current year.

Insider Buying and Selling

In related news, Chairman Gabriel Mecklenburg sold 200,000 shares of the company’s stock in a transaction dated Monday, October 12th. The stock was sold at an average price of $103.13, for a total transaction of $20,626,000.00. Following the transaction, the chairman directly owned 200,000 shares of the company’s stock, valued at $20,626,000. This represents a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Perez sold 4,100 shares of the company’s stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $100.20, for a total value of $410,820.00. Following the completion of the transaction, the chief executive officer directly owned 4,100 shares in the company, valued at approximately $410,820. The trade was a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,024,581 shares of company stock worth $95,632,761 in the last three months. 18.92% of the stock is owned by company insiders.

Institutional Trading of Hinge Health

Several large investors have recently bought and sold shares of the business. Alps Advisors Inc. acquired a new stake in shares of Hinge Health in the 3rd quarter worth $595,000. Ashton Thomas Private Wealth LLC purchased a new position in shares of Hinge Health during the 3rd quarter worth $458,000. CenterBook Partners LP acquired a new position in shares of Hinge Health during the 3rd quarter valued at about $856,000. Calamos Advisors LLC acquired a new position in shares of Hinge Health during the 3rd quarter valued at about $4,779,000. Finally, Kestra Advisory Services LLC purchased a new stake in shares of Hinge Health in the third quarter valued at about $242,000.

Key Headlines Impacting Hinge Health

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Q3 results exceeded expectations: Hinge Health reported earnings of $0.71 per share versus consensus estimates of $0.27 and revenue of $234.97 million, up 52.4% year over year. The company also posted a 15.15% net margin and 51.6% return on equity. Hinge Health quarterly earnings report
• Positive Sentiment: Revenue outlook was raised above consensus: Hinge Health guided fourth-quarter 2026 revenue to $249 million-$251 million, compared with the $239.2 million consensus estimate. Full-year revenue guidance of $879 million-$881 million also exceeded the $858.5 million consensus. Hinge Health revenue outlook
• Positive Sentiment: Analysts raised price targets: RBC lifted its target to $135 and maintained an “outperform” rating; Canaccord raised its target to $134 with a “buy” rating; and Stifel increased its target to $135, also retaining a “buy” rating. These targets imply roughly 16% upside from recent trading levels.
• Neutral Sentiment: Management highlighted continued expansion of its technology-enabled care platform and is targeting an integrated gastrointestinal program in summer 2027, providing a potential longer-term growth catalyst.
• Negative Sentiment: The earnings beat may have been largely anticipated, and some coverage indicated results missed the higher “whisper” expectations. With HNGE trading near its 52-week high and at a high valuation, investors may be taking profits despite the favorable fundamental update. Hinge Health earnings expectations analysis

Hinge Health Company Profile

Hinge Health is a digital healthcare company focused on musculoskeletal (MSK) conditions, including back and joint pain. The company provides virtual care programs designed to help members manage pain, improve mobility and reduce the need for more costly or invasive treatments.

Its platform combines personalized exercise therapy, behavioral support, education and access to clinical professionals. Hinge Health also uses technologies such as motion-sensing wearable devices and artificial intelligence to help guide exercises, monitor progress and tailor care plans to individual needs.

Hinge Health primarily serves employers and health plans, which offer its programs to eligible members in the United States.